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Abstract Human L-defensin-2 (HBD-2) gene expression is in-
duced by tumour necrosis factor-K, interleukin-1L and lipopoly-
saccharide. The objective of this study was to investigate the
e¡ect of neutrophil elastase (NE), a major pro-in£ammatory
protease, on HBD-2 expression. HBD-2 gene expression was
assessed by reverse transcription polymerase chain reaction in
the human bronchial epithelial cell line 16HBE14o3 and pri-
mary normal human bronchial epithelial (NHBE) cells. Optimal
HBD-2 expression was induced with 100 nM NE. Using a
HBD-2-luciferase reporter construct, luciferase activity in-
creased signi¢cantly in 16HBE14o3 cells following incubation
with NE. An increase in HBD-2 protein expression was ob-
served in primary NHBE cells after incubation with NE as
assessed by laser scanning cytometry. In conclusion, NE up-
regulates HBD-2 expression in bronchial epithelial cells.
1 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
Key words: Human L-defensin-2; Neutrophil elastase;
Innate immunity
1. Introduction
Neutrophil elastase (NE) is a serine protease speci¢cally
expressed by neutrophils and stored in their primary granules
[1]. It is an omnivorous protease, which is capable of degrad-
ing a wide variety of proteins and has been implicated in the
pathogenesis of a number of lung diseases including cystic
¢brosis (CF), pneumonia and emphysema [2^4]. However,
recent evidence points towards NE directly participating in
the process by which neutrophils kill bacteria [5]. Comparison
of wild type and NE de¢cient (NE3/3) mice has revealed that
NE3/3 mice are more susceptible than their normal litter-
mates to sepsis and death following intraperitoneal infection
with Gram-negative bacteria [6]. Further studies have revealed
that NE can cleave virulence products of Shigella, Salmonella
and Yersinia [7]. NE can also impair host defence mechanisms
by cleaving immunoglobulin and complement receptors [8].
Apart from its antibacterial activity, NE has been shown to
up-regulate interleukin (IL)-8 expression by epithelial cells via
a MyD88/IRAK/TRAF-6 pathway [9]. Due to the large NE
burden in the CF lung, NE activation of IL-8 expression may
lead to further neutrophil recruitment to the lung thus setting
up a cycle of in£ammation.
Not all factors secreted by the respiratory tract are pro-
in£ammatory. A number of proteins expressed by the respi-
ratory tract play a part in host defence including the small
cationic L-defensins. Four L-defensin proteins have been iso-
lated, human L-defensin 1, 2, 3 and 4 (HBD-1, -2, -3 and -4),
and many more L-defensin genes have been identi¢ed follow-
ing a genomewide search [10]. HBD-1^4 are expressed by ep-
ithelial cells either constitutively or up-regulated in response
to bacterial or pro-in£ammatory stimuli [11].
In this report we demonstrate that NE up-regulates HBD-2
expression in human bronchial epithelial (HBE) cells. This
result indicates that apart from having a direct bactericidal
e¡ect, NE can also up-regulate antimicrobial peptides such
as HBD-2, which also have microbicidal activity. This activity
of NE may be particularly important in the setting of acute
infection in which NE participates in bacterial clearance, both
directly and indirectly.
2. Materials and methods
2.1. Culture and stimulation of airway epithelial cells
Primary airway normal human bronchial epithelial (NHBE) cells
(Clonetics Bio Whittaker, Wokingham, UK) were cultured in
BEGM0 BulletKit0 medium supplied by the manufacturer. Before
stimulation cells were seeded on a six-well plate (Greiner, Solingen,
Germany) at 1U106 cells/well and allowed to adhere. Cells were then
treated with NE (Elastin Products, Owensville, MO, USA) at doses of
0, 50 and 100 nM and cultured for 24 h before harvesting.
Lab-Tek chamber slides (Nalgene Nunc, Roskilde, Denmark) were
seeded with NHBE cells at 1U105 cells per well. Cells were treated
with 10 nM NE. Stimulation was blocked with recombinant 50 nM
K1-antitrypsin (K1AT, Sigma-Ireland, Tallaght, Dublin, Ireland).
HBE cells 16HBE14o3 (a gift from Dr Gruenert, University of
Vermont, VT, USA) were cultured in minimum essential medium
(Gibco BRL, Karlsruhe, Germany) containing 10% foetal calf serum
(FCS). Before stimulation 1U106 cells/well were cultured in a six well
plate for 24 h in FCS-free medium and were incubated with NE at
0^100 nM. Cells were cultured for 24 h before harvesting.
2.2. Laser scanning cytometry (LSC)
NHBE cells were washed in phosphate-bu¡ered saline (PBS) and
blocked with 2% bovine serum albumin and slides prepared as above
were incubated at room temperature for 15 min. A 1:100 dilution of
goat anti-HBD-2 antibody (a gift from Dr Paul McCray, University
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of Iowa, Iowa City, IA, USA) or 1:1000 dilution of 1 mg/ml stock of
isotype goat IgG was added and incubated at 4‡C in the dark for
30 min. Slides were washed three times in PBS and probed with 1:10
dilution of anti-goat IgG £uorescein isothiocyanate (FITC, Dako,
Glostrup, Denmark) at 4‡C in the dark for 30 min. The washing
step was repeated and cells were permeabilised in a 1:1 ratio of per-
meabilisation solution (Dako) and 0.2 Wg/ml solution of propidium
iodide (PI, Molecular Probes, Leiden, The Netherlands). Slides were
washed in PBS and HBD-2 expression was quanti¢ed on a Compu-
Cyte laser scanning cytometer (CompuCyte, Cambridge, MA, USA).
FITC and PI cellular £uorescence of at least 5U103 cells were mea-
sured. The threshold contour was set on red £uorescence to detect all
PI-stained nuclei. Arti¢cially contoured debris was gated out based on
contour size. Aggregated cells were gated out using an algorithm in
the LSC software that ¢nds and marks multiple cells. Individual
HBD-2-expressing cells were identi¢ed and quanti¢ed using Compu-
Cyte software on the basis of integrated green £uorescence re£ecting
binding of anti-goat FITC antibody.
2.3. Semiquantitative reverse transcriptase polymerase chain reaction
(RT-PCR)
After treatment cells were harvested in Tri reagent (Sigma-Ireland)
and RNA was extracted as detailed in the manufacturer’s protocol.
RNA (1 Wg) was reverse-transcribed at 42‡C using the ¢rst strand
cDNA synthesis kit for RT-PCR (Roche, Lewes, UK) with 1 mM
deoxynucleotide mix, 1.6 Wg oligo-p[dT]15 primer and 0.8 Wl AMV
reverse transcriptase in a 20 Wl volume as described in the manufac-
turer’s protocol. 2 Wl of each cDNA was ampli¢ed with 1.25 U Taq
DNA polymerase, 1UPCR bu¡er and 10 mM dNTPs (Promega,
Southampton, UK) in a 50 Wl volume containing 100 pmol each of
the following primers: 5P-GGT ATA GGC GAT CCT GTT ACC
TGC-3P (sense) and 5P-TCA TGG CTT TTT GCA GCA TTT TGT
TC-3P (antisense) for HBD-2; 5P-AAC TCT GGT AAA GTG GAT-
3P (sense) and 5P-TAC TCA GCG CCA CCA GCA TCG-3P (anti-
sense) for GAPDH. After a hot start the ampli¢cation pro¢le for
HBD-2 was 32 cycles of 1 min denaturation at 94‡C, 1 min annealing
at 58‡C and 1 min extension at 72‡C. RT-PCR ampli¢cation of HBD-
2 and GAPDH generated products of 174 bp and 211 bp respectively.
2.4. Densitometric analysis of PCR results
PCR products were resolved on a 1% agarose gel containing 0.5 Wg/
ml ethidium bromide (Sigma). The gels were analysed by densitometry
and compared in a semiquantitative manner using ImageMaster0
TotalLab Software (Amersham Pharmacia, Amersham, UK). The ra-
tio of PCR fragment intensities of HBD-2 relative to GAPDH was
determined. All expression values were veri¢ed by at least two inde-
pendent RT-PCRs.
2.5. Transfection and reporter gene studies
To construct the HBD-2 luciferase reporter plasmid, the human
HBD-2 promoter was PCR-ampli¢ed using Vent Polymerase (New
England Biolabs, Herts., UK) from genomic DNA with 5P-GG-
CTCGAGGCTCAGACATCAGCACCCAAA-3P (forward) and 5P-
AAAAGCTTGAGTCTGGGGAGGACATCAA-3P (reverse), and
was cloned on a XhoI-HindIII fragment (underlined) into the pGL3-
PV plasmid (Promega). HBE cells were seeded at 5U104 on coated
24-well plates 24 h before transfection. Transfections were performed
with TransFast Transfection Reagent (Promega) in a 1:1 ratio accord-
ing to the manufacturer’s instructions, using 1 Wg of HBD-2 luciferase
plasmid. Uniform transfection e⁄ciencies were achieved by initially
optimising transfection conditions using a constitutive luciferase ex-
pression vector, pGL3-control (Promega). Transfections were incuba-
ted for 1 h at 37‡C. Cells were then supplemented with additional
growth medium (1 ml/well) for 48 h at 37‡C before being left un-
treated or stimulated with NE as indicated. Cells were lysed with
Reporter Lysis Bu¡er (1U) (Promega) (300 Wl/well), protein concen-
trations were determined, and reporter gene activity was quanti¢ed by
luminometry (Wallac Victor2, 1420 multilabel counter, Turku, Fin-
land) using the Promega luciferase assay system according to the
manufacturer’s instructions.
2.6. Statistical analysis
Data were analysed with GraphPad Prism 3.0 software package
(GraphPad Software, San Diego, CA, USA). Results are expressed
as meanOS.E.M. and were compared by Mann^Whitney one-tailed
test. Di¡erences were considered signi¢cant when the P value was
9 0.05.
3. Results
3.1. Up-regulation of HBD-2 mRNA by NE
Inducibility of antimicrobial factors such as L-defensins by
bacterial products and/or in£ammatory mediators is a key
feature of the immune response. To evaluate the e¡ect of
NE on HBD-2 mRNA levels by RT-PCR, (1U106)
16HBE14o3 cells and NHBE primary cells were incubated
for 24 h with 0, 50 or 100 nM NE. HBD-2 mRNA expression
increased signi¢cantly in both 16HBE14o3 cell line and
NHBE primary cells after treatment with 50 (P9 0.05) and
100 (P9 0.05) nM NE (Fig. 1A,B).
3.2. HBD-2 surface protein expression in NHBE primary cells
LSC analysis using a HBD-2 primary antibody and an anti-
goat FITC-labelled secondary antibody was carried out on
NHBE primary cells. HBD-2 surface protein expression in-
creased after treatment with 30 Wg lipopolysaccharide (LPS)
for 24 h (Fig. 2A). 10 nM NE treatment of cells for 24 h
Fig. 1. HBD-2 mRNA expression is up-regulated by NE. Analysis of gene expression of HBD-2 in cultured 16HBE14o3 cell line (A) and pri-
mary NHBE cells (B) using RT-PCR. 1U106 cells seeded on a six-well plate were treated with 0, 50, or 100 nM NE for 24 h and revealed
HBD-2- (174 bp) and GAPDH- (211 bp) speci¢c ampli¢cation products.
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signi¢cantly elevated protein expression compared with con-
trol cells (P9 0.05) (Fig. 2B). Pre-treatment with 50 nM
K1AT decreased HBD-2 protein expression to that of control
or untreated cells (Fig. 2C,D).
3.3. E¡ect of nM concentrations of active NE on
HBD-2 promoter activity
To investigate the regulation of HBD-2 mRNA expression
in 16HBE14o3 cells by NE, the HBD-2 promoter was ampli-
¢ed by PCR and subcloned into a luciferase reporter plasmid
pGL3-Basic. 16HBE14o3 cells were transfected with the con-
struct and stimulated with NE. Treatment of cells with 20 and
50 nM NE for 4 h increased the relative luciferase activity
signi¢cantly (P9 0.05) (Fig. 3).
4. Discussion
This report is the ¢rst identifying NE as a stimulus for the
up-regulation of HBD-2 mRNA and surface protein expres-
sion.
L-Defensins are antimicrobial peptides that protect the ep-
ithelial mucosa from bacterial infection and colonisation. The
¢rst human L-defensin, HBD-1, was isolated as a trace peptide
from human haemo¢ltrates, its mRNA is predominantly ex-
pressed in epithelia of the urogenital tract [12^14]. HBD-2 and
HBD-3 are highly expressed in in£amed skin but all three
L-defensins are also expressed in epithelia of the trachea and
lung [15^17]. Gene expression of HBD-1 has been reported to
be constitutive whereas HBD-2 gene expression is inducible by
various pro-in£ammatory agents such as tumour necrosis fac-
tor-K, IL-1L, LPS, bacteria and yeasts, stimuli commonly
found in lung infection and in£ammation [10,11,18].
The inducible nature of HBD-2 suggests it may play an
important role in innate immune defence. It acts as a host
defence molecule whose production is induced in response
to infection thus maintaining a pathogen-free environment.
HBD-2 is expressed in epithelia of the inner and outer surfa-
ces of the human body such as the skin, the respiratory tract
and the gastrointestinal tract. HBD-2 is also expressed in dis-
eased tissue such as psoriatic skin, the CF lung and the gastric
mucosal tissue in response to Helicobacter pylori infection
[16,19,20]. We have previously shown that NE up-regulates
IL-8 via NF-UB; therefore, due to the presence of NF-UB-
like consensus binding sequences on the 5P £anking region
of the HBD-2 gene, we construed that HDB2 expression
may also up-regulated by NE. This was shown for the ¢rst
time in this study.
NE is a serine protease expressed at the promyelocytic stage
of neutrophil development and stored in azurophilic granules
in mature neutrophils. Apart from having an enormous elas-
tolytic potential, recent studies have demonstrated that NE
has important antibacterial properties. Survival of NE3/3
mice is decreased following infection with Gram-negative bac-
teria [6]. In addition, neutrophil proteases, not oxidants, are
primarily responsible for neutrophil activity against staphylo-
coccal and fungal infections [7,21]. It has been shown that the
bacterial cell wall protein, OmpA, is a prime target for NE
cleavage and degradation although other proteins in Gram-
negative bacteria may also be targeted by NE [22]. In this
regard production of NE may be bene¢cial in the normal
lung during acute infection, facilitating clearance of bacteria
from the respiratory tract [23]. In addition, in this study we
have shown the release of NE onto the epithelial surface of
the respiratory tract may lead to increased expression of
HBD-2, which will also participate in bacterial killing.
In conclusion, although the deleterious e¡ects of NE have
previously been described, such as impairment of mucociliary
clearance, increased mucin production [24] and cleavage of
immunoglobulin and complement receptors, NE is clearly
bene¢cial in host defence by directly killing bacteria and, as
shown in this study, by up-regulating the expression of the
antimicrobial peptide HBD-2.
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Fig. 2. Representative histograms of HBD-2 surface protein expres-
sion. Lab-Tek chamber slides were seeded with NHBE cells at
1U105 cells/well. A: Histogram showing HBD-2 expression in un-
treated cells (clear) and after treatment with 30 Wg LPS (black) for
24 h. B: Histogram representing HBD-2 expression in untreated
cells (clear) and after treatment with 10 nM NE (black) for 24 h.
C: Histogram shows HBD-2 expression returns to that of unstimu-
lated cells (clear) after inhibition with K1AT (black). D: Bar graph
representing the median peak values for each treatment in C.
Fig. 3. E¡ect of NE on induction of HBD-2 promoter activity of
pGL3 luciferase construct in 16HBE14o3 cells. Transfected cells
were incubated for 4 h with the indicated doses of NE before assay
of luciferase activity.
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